Remove Company Remove High Tech Remove Incubator Remove Seed Funding
article thumbnail

Investors Love Top Startup Incubator Graduates

Startup Professionals Musings

Business incubators for sharing services were all the rage back in the days of the dot-com bubble (700 for profit, many more non-profit). Now they are coming back, and the best even provide networking, technical leadership, and seed funding, as well as investors waving money at graduates.

article thumbnail

The Best Startup Incubators Have the Best People

Startup Professionals Musings

Business incubators for sharing services were all the rage back in the days of the dot-com bubble (700 for profit, many more non-profit). Now they are coming back, and the best even provide networking, technical leadership, and seed funding, as well as shared facilities and space.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Startup Accelerators are Entrepreneur Boot Camps

Startup Professionals Musings

Business incubators for sharing services were all the rage back in the days of the dot-com bubble (700 for profit, many more non-profit). Now they are coming back, and the best even provide networking, technical leadership, and seed funding, as well as investors waving money at graduates.

article thumbnail

Interview with Erik Rannala, MuckerLab

socalTECH

Erik Rannala: MuckerLab is a new startup accelerator, focused on incubation stage Internet, software, services, and media businesses here in LA. First and foremost, we're focused on making companies become successful. We're providing seed funding, office space, and put them through a three month, structured program.

article thumbnail

Biotech Roundup: Deals Gone Wrong, Ethical Red Flags & Bay Goodbyes

Xconomy

A company official told Xconomy the drug would be priced in line with standard of care enzyme replacement therapy, which costs around $300,000 per patient, per year. Contravir will pay $17 million in cash and 10 percent of its equity to Ciclofilin shareholders, but only if the company’s lead drug, CPI-431-32, hits certain milestones.

article thumbnail

US Economic Risks (Sept 2010): Impact on Investors & Entrepreneurs

Both Sides of the Table

This has been especially true for angels or seed investors as there is a new thesis that less capital is needed to start Internet companies so more money is being spent at this phase of the funding lifecycle. companies did not participate in the first phase and consequently were not in the running for all that followed.